Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.

M S Lagonigro1, E Tamborini, T Negri

  • 1Experimental Molecular Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

The Journal of Pathology
|February 14, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between elevated prolactin levels and circulating erythroid precursors in dialyzed patients.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2000
Same author

Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma.

Leukemia·2000
Same author

The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma.

Leukemia·2000
Same author

Can Reed-Sternberg cells of classic Hodgkin's disease be considered B-cells?

Advances in clinical pathology : the official journal of Adriatic Society of Pathology·2000
Same author

Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma.

Cancer·2000
Same author

Neoplastic complications of HIV infection.

Annals of oncology : official journal of the European Society for Medical Oncology·2000

Conventional central primary chondrosarcomas (CCS) co-express PDGFRalpha and PDGFRbeta, with PDGFRbeta showing higher activation. This suggests receptor tyrosine kinases (RTKs) as potential therapeutic targets for chondrosarcoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chondrosarcomas are a significant subset of primary bone sarcomas.
  • Identifying molecular targets is crucial for developing novel chondrosarcoma therapies.

Purpose of the Study:

  • To investigate the expression and activation of PDGFRalpha, PDGFRbeta, and KIT receptor tyrosine kinases (RTKs) in conventional central primary chondrosarcomas (CCS).
  • To evaluate these RTKs as potential therapeutic targets for chondrosarcoma.

Main Methods:

  • Immunohistochemistry (IHC) for RTK expression.
  • Immunoprecipitation and Western blot for expression and activation status.
  • cDNA screening for mutations, RT-PCR for ligand presence, and FISH for gene amplification.

Related Experiment Videos

Main Results:

  • CCS co-expressed PDGFRalpha and PDGFRbeta; PDGFRbeta exhibited higher protein expression and phosphorylation.
  • KIT did not appear to play a significant role in CCS.
  • PDGFRbeta was expressed but not activated in healthy cartilage, unlike in CCS.

Conclusions:

  • Findings suggest an autocrine/paracrine loop activation of PDGFRalpha and PDGFRbeta in CCS.
  • The identified RTK profile supports the use of RTK inhibitors for chondrosarcoma treatment, potentially combined with chemotherapy.
  • Further research into RTKs and their downstream signaling pathways in chondrosarcoma is warranted.